A personalized vaccine for patients with glioblastoma produced a safe and effective immune response, according to a study published May 12 in Nature Cancer.
A phase 1 clinical trial of the vaccine was conducted at St. Louis-based Siteman Cancer Center and co-led by researchers from St. Louis-based Washington University School of Medicine and Somerville, Mass.-based Mass General Brigham.
Here are three notes on the study:
- The vaccine uses engineered DNA molecules to activate the immune system to seek out and eliminate up to 40 cancer proteins unique to each patient’s tumor, a May 12 news release from WashU Medicine said.
- Glioblastoma tumors hide from the immune system, making them harder to treat. The vaccine was able to transform the tumors, making them more susceptible to eradication, the release said.
- Of the nine adult patients enrolled in the trial, two-thirds had no cancer progression six months after surgery, two-thirds survived one year and one-third survived two years.
One patient is alive and remains cancer free today, about five years since her diagnosis.
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
